uniQure (NASDAQ:QURE) Stock Price Up 5.2% After Analyst Upgrade

uniQure (NASDAQ:QURE) shares shot up 5.2% during mid-day trading on Friday after The Goldman Sachs Group raised their price target on the stock from $9.00 to $20.00. The Goldman Sachs Group currently has a neutral rating on the stock. uniQure traded as high as $15.89 and last traded at $15.85. 460,962 shares traded hands during trading, a decline of 72% from the average session volume of 1,640,178 shares. The stock had previously closed at $15.06.

Several other equities analysts have also weighed in on QURE. StockNews.com upgraded shares of uniQure to a “sell” rating in a report on Wednesday. Royal Bank of Canada boosted their price objective on uniQure from $14.00 to $20.00 and gave the stock an “outperform” rating in a research note on Wednesday. Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and increased their target price for the company from $20.00 to $52.00 in a research note on Tuesday. Wells Fargo & Company upgraded uniQure from a “hold” rating to a “strong-buy” rating in a report on Tuesday. Finally, Leerink Partners increased their price objective on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research report on Wednesday. One analyst has rated the stock with a sell rating, two have assigned a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $32.14.

Insider Buying and Selling at uniQure

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the sale, the chief executive officer now owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. The trade was a 0.57 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.74% of the stock is owned by insiders.

Hedge Funds Weigh In On uniQure

A number of hedge funds have recently bought and sold shares of the company. RTW Investments LP acquired a new stake in uniQure during the third quarter valued at approximately $49,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of uniQure by 57.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 3,663 shares during the last quarter. Atria Investments Inc acquired a new stake in shares of uniQure during the 3rd quarter valued at approximately $53,000. Quarry LP bought a new position in uniQure during the third quarter worth $58,000. Finally, Vanguard Personalized Indexing Management LLC boosted its holdings in uniQure by 21.0% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 2,306 shares during the period. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Trading Up 5.2 %

The stock has a market cap of $772.53 million, a price-to-earnings ratio of -3.04 and a beta of 0.89. The business’s fifty day simple moving average is $6.85 and its 200 day simple moving average is $6.28. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.21. The business had revenue of $2.29 million during the quarter, compared to analyst estimates of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. On average, research analysts predict that uniQure will post -3.81 EPS for the current year.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.